PriceTargets.com logo

Solaris Resources - SLS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 2 Strong Buy Ratings
C$6.15 As of 02/9/2021 12:59 AM ET
▼ -0.17 (-2.69%)

This chart shows the closing price for SLS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
MarAprC$6.15Closing price on 04/27/25:
Get New Solaris Resources Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SLS

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 3 analysts offering 12 month price targets for Solaris Resources in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$6.15.

This chart shows the closing price for SLS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
6/249/2412/243/254/255/26C$4.30C$4.92C$5.54C$6.15C$6.77Closing price on 04/27/25: C$6.15HighC$0.0000AverageC$0.0000LowC$10.00M




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Solaris Resources. This rating has held steady since February 2025, when it changed from a Strong Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 2 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 3 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024
  • 3 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2025
  • 2 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/29/2025
  • 2 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/28/2025

Latest Recommendations

  • 2 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2025Maxim GroupDowngradeStrong-Buy ➝ Hold
8/12/2024HC WainwrightUpgradeStrong-Buy
7/3/2024Maxim GroupUpgradeStrong-Buy
6/10/2024National Bank FinancialUpgradeStrong-Buy
(Data available from 4/28/2020 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/29/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/28/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/27/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/29/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/28/2025

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Solaris Resources logo
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Read More

Today's Range

Now: C$6.15
Low: C$5.95
High: C$6.35

50 Day Range

MA: C$6.15
Low: C$6.15
High: C$6.15

52 Week Range

Now: C$6.15
Low: C$1.38
High: C$7.09

Volume

53,313 shs

Average Volume

132,199 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Solaris Resources?

The following Wall Street analysts have issued reports on Solaris Resources in the last year: HC Wainwright, Maxim Group, and National Bank Financial.
View the latest analyst ratings for SLS.

What is the current price target for Solaris Resources?

0 Wall Street analysts have set twelve-month price targets for Solaris Resources in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Solaris Resources in the next year.
View the latest price targets for SLS.

What is the current consensus analyst rating for Solaris Resources?

Solaris Resources currently has 1 hold rating and 2 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SLS will outperform the market and that investors should add to their positions of Solaris Resources.
View the latest ratings for SLS.

What other companies compete with Solaris Resources?

Other companies that are similar to Solaris Resources include Cybin, EQ, FRX Innovations, IM Cannabis and ImmunoPrecise Antibodies. Learn More about companies similar to Solaris Resources.

How do I contact Solaris Resources' investor relations team?

Solaris Resources' physical mailing address is 7 TIMES SQUARE, SUITE 2503, NEW YORK, NY, 10036. The company's listed phone number is (646) 200-5278. The official website for Solaris Resources is sellaslifesciences.com. Learn More about contacing Solaris Resources investor relations.